TCM
SUPN icon

TD Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

TD Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$103 – 855
2026
Q1 		$103 Sell
2
-2
-50% -$102 ﹤0.01% 841
2025
Q4 		$199 Buy
+4
New +$194 ﹤0.01% 795
2021
Q1 		– Sell
-1,492
Closed -$38K – 338
2020
Q4 		$38K Buy
+1,492
New +$32.1K 0.01% 145

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

TD Capital Management's SUPN Position: Q2 2026 in Review

TD Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 2 shares — an estimated $103 sold.

TD Capital Management first reported a position in SUPN in Q4 2020 and held it in 3 quarters. The position peaked at $38K in Q4 2020. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • TD Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • TD Capital Management sold 2 Supernus Pharmaceuticals shares in Q2 2026, an estimated $103.
  • TD Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • TD Capital Management's Supernus Pharmaceuticals position peaked at $38K in Q4 2020.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on TD Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.